FLC News

Lab Spotlight: NIAID - RSV Vaccine Candidate

NIAID RSV Vaccine Protein

The Structural Biology Section (SBS) of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center’s Virology Laboratory, led by Dr. Peter Kwong, applies the tools of computational biology and structural bioinformatics to the design of effective viral vaccine candidates.

Globally, respiratory syncytial virus (RSV) affects an estimated 64 million people and causes 160,000 deaths annually. Kwong, along with Dr. Barney Graham and other colleagues, stabilized an RSV recombinant prefusion F protein (pre-F, pictured) to develop an RSV vaccine. Stabilized pre-F displays epitopes that are not present in postfusion F protein. The insights gleaned from the RSV work on stabilization of the F protein in the prefusion conformation are being applied to other viral pathogens, including HIV-1 and human metapneumovirus (hMPV.)

Image courtesy of NIAID.

FLC News